[1] | Glazier R. Managing early presentation of rheumatoid arthritis: Systematic overview. Can Fam Physician 1996; 42: 913-22. |
[2] | J. Breckling, Ed., The Analysis of Directional Time Series: Applications to Wind Speed and Direction, ser. Lecture Notes in Statistics. Berlin, Germany: Springer, 1989, vol. 61.Bauerová K, Bezek, A. Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis. Gene PhysiolBiophys 1999; 18: 15-20. |
[3] | Halliwell B. Free radicals, antioxidants and human diseases: curiosity, cause or consequence. Lancet 1994; 344: 721-724. |
[4] | Gutteridge JM. Free radicals in disease processes: a complication of cause and consequence. Free Radical Res Commun 1993; 19: 141-158. |
[5] | Gambhir JK, Lali P, Jain AK. Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. ClinBiochem1997;30: 351-355. |
[6] | Mackness B, Durrington PN, Mackness MI. The paraoxonase gene family and coronary heart disease. CurrOpinLipidol 2002;13: 357-62. |
[7] | Nakanishi M, Takanami Y, Maruyama T et al. The ratio of serum paraoxonase/arylesterase activity using an improved assay for arylesterase activity to discriminate PON1(R192) from PON1(Q192).J AtherosclerThromb 2003; 10(6): 337-42. |
[8] | Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis.ArteriosclerThrombVascBiol2001; 21(4):473-80. |
[9] | Shin BS. Paraoxonase gene polymorphism in south-western Korean population.J Korean Med Sci 2009; 24(4): 561-6. |
[10] | Flekac M, Skrha J, Zídková K et al. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res 2008; 57(5): 717-26. |
[11] | Aubo C, Senti M, Marrugat J et al. Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. Eur H J 2000; 21: 33-8. |
[12] | Adkins S, Gan KN, Mody M et al. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A and B allozymes. Am J Hum Genet 1993; 52: 598-608. |
[13] | Agachan B, Yilmaz H, Ergen HA, Karaali ZE, Isbir T. Paraoxonase (PON1) 55 and 192 polymorphism and its effects to oxidant-antioxidant system in turkish patients with type 2 diabetes mellitus. Physiol Res. 2005; 54(3): 287-93. |
[14] | Aviram M, Billecke S, Sorenson R et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities.ArteriosclerThrombVascBiol1998; 18: 1617-1624. |
[15] | Mackness B, MacknessMi, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett1998; 423: 57-60. |
[16] | Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214-227. |
[17] | Mackness MI, Harty D, Bhatnagar D et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-199. |
[18] | Kilic SS, Aydin S, Kilic N, Erman F, Aydin S, Celik I. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis.World JGastroenterol. 2005; 11(46): 7351-4. |
[19] | Halliwell B & Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J ClinNutr 1993; 57: 715-725. |
[20] | Miller SA, Dykes DD, Polesky HS. Simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1998; 16: 1215. |
[21] | Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genetics 1993; 3: 73-76. |
[22] | Coenen MJ and Gregersen PK. Rheumatoid arthritis: a view of the current genetic landscape.Genes Immun. 2009; 10(2):101-11. |
[23] | Nathaniel Treister BA, Michael Glick DMD. Rheumatoid Arthritis: A Review And Suggested Dental Care Considerations. J Am Dent Assoc. 1999; 130(5): 689-98. |
[24] | Giles JT, Bartlett SJ, Andersen R, Thompson R, Fontaine KR, Bathon JM. Association of body fat with C-reactive protein in rheumatoid arthritis.Arthritis Rheum 2008; 8(9): 2632-41. |
[25] | Cerhan JR, Saag KG, Merlino LA, Mikuls TR, Criswell LA. Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older women. Am J Epidemiol 2003; 157: 345-354. |
[26] | Heliovaara M, Knekt P, Aho K, Aaran RK, Alfthan G, Aromaa A. Serum antioxidants and risk of rheumatoid arthritis. AnnRheum 1994, 53:51-53. |
[27] | Hagfors L, Leanderson P, Skoldstam L, Andersson J, Johansson G. Antioxidant intake, plasma antioxidants and oxidative stress in a randomized, controlled, parallel, Mediterranean dietary intervention study on patients with rheumatoid arthritis. Nutr J 2003; 30: 2-5. |
[28] | Bae SC, Kim SJ, Sung MK. Inadequate antioxidant nutrient intake and altered plasma antioxidant status of rheumatoid arthritis patients. J Am CollNutr 2003; 22: 311-315. |
[29] | Hitchon CA, El-Gabalawy HS. Oxidation in rheumatoid arthritis.Arthritis Res Ther 2004; 6: 265-78. |
[30] | Merry P, Grootveld M, Lunec J, Blake DR. Oxidative damage to lipids within the inflamed human joint provides evidence of radical-mediated hypoxic-reperfusion injury.Am J ClinNutr 1991; 53: 362S-369S. |
[31] | Ozgunes H, Gurer H, Tuncer S. Correlation between Plasma Malondialdehyde and ceruloplasmin activity values in rheumatoid arthritis. ClinBiochem1995; 28(2): 193-194. |
[32] | Taysi S, Polat F, Gul M, Sari RA, Bakan E. Lipid peroxidation, some extracellular antioxidant and antioxidant enzymes in serum of patients with rheumatoid arthritis. RheumatolInt 2002; 21(5):200-4. |
[33] | Karatas F, Ozates I, Canatan H, Halifeoglu I, Karatepe M, Colakt R. Antioxidant status & lipid peroxidation in patients with rheumatoid arthritis. Indian J Med Res 2003; 118: 178-81. |
[34] | Jaswal S, Mehta HC, Sood AK, Kaur J. Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. ClinChimActa 2003; 338(1-2): 123-129. |
[35] | Baskol G, Demir H, Baskol M etal. Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. ClinBiochem 2005; 38(10): 951-955. |
[36] | Sarban S, Kocyigit A, Yazar M, Isikan UE. Plasma total antioxidant capacity, lipid peroxidation, and erythrocyte antioxidant enzyme activities in patients with rheumatoid arthritis and osteoarthritis. ClinBiochem 2005; 38(11): 981-986. |
[37] | Seven A, Güzel S, Aslan M, Hamuryudan V. Lipid, protein, DNA oxidation and antioxidant status in rheumatoid arthritis. ClinBiochem2008; 41: 538-543. |
[38] | James RW, Deakin SP. The importance of high density lipoproteins for Paraoxonase 1 secretion, stability and activity. Free RadicBiol& Med. 2004; 37 (12):1986-1994. |
[39] | Tanimoto N, Kumon Y, Suehiro T etal. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci. 2003; 72(25): 2877-2885. |
[40] | Vottery R, Saigal R, Singhal N, Gupta BS. Lipid profile in rheumatoid arthritis and its relation to disease activity.J Assoc Physicians India. 2001; 49: 1188-90. |
[41] | Altinadg O, Karakoc M, Soran N, Celik H, Celik N, Selek F. Paraoxonase and arylesterase activities in patients with rheumatoid arthritis. Rheumatism 2007; 22: 132-6. |
[42] | Isik A, Koca SS, Ustundag B, Celik H, Yildirim A. Paraoxonase and arylesterase levels in rheumatoid arthritis. ClinRheumatol. 2006; 26: 342-8. |
[43] | Nakamura K, Endo H, Kashiwazaki S. Serum oxidation activities and rheumatoid arthritis. Int J Tissue React 1987; 9:307-16. |
[44] | Tripi LM, Manzi S, Chen Qetal. Relationship of Serum Paraoxonase 1 Activity and Paraoxonase 1 Genotype to Risk of Systemic Lupus Erythematosus. Arthritis Rheum. 2006; 54 (6): 1928-1939. |
[45] | Sidoti A, Antognelli C, Rinaldi C. etal. Glyoxalase I A111E, paraoxonase 1 Q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis. MultScler 2007; 13 (4):446-53. |
[46] | Sidoti A, Antognelli C, Rinaldi C. etal. Glyoxalase I A111E, paraoxonase 1 Q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis. MultScler 2007; 13 (4):446-53. |
[47] | Charles-Schoeman C, Lee YY, Shahbazian A, Gorn AH, Fitzgerald J, Ranganath VK, Taylor M, Ragavendra N, McMahon M, Elashoff D, Reddy ST. Association of Paraoxonase 1 gene polymorphisms and enzyme activity with carotid plaque in rheumatoid arthritis.Arthritis Rheum. 2013[Epub ahead of print]. |